Abstract
Converging evidence suggests a possible link between thyroid state and Alzheimers disease (AD), including a higher probability of dementia in individuals with higher TSH levels and a two-fold risk of AD in patients with hypothyroidism. Thyroid hormones modulate factors associated with AD, including amyloid precursor protein expression in the brain, suggesting a possible role for thyroid hormone in AD pathology. The present study is the first to directly evaluate brain thyroid hormone levels in AD. Triiodothyronine (T ) and thyroxine (T ) levels were measured with radioimmunoassay (RIA) in post-mortem samples of prefrontal cortex of patients with pathologically confirmed AD, including Braak stage I-II (n=8), Braak stage V-VI (n=8), and controls without any primary neurological disease (n=8). T levels did not differ between groups. T levels were significantly lower in Braak stage V-VI brains relative to controls, but there was no statistically significant difference between T levels in Braak stage I-II versus controls. Results suggest that the conversion of T to T may be affected in advanced AD, perhaps due to alterations in deiodinase activity. Reduced conversion of T to T3 in AD may be associated with both AD pathology and the clinical presentation of dementia.
Keywords: Thyroid hormones, thyroxine, Alzheimer's disease, dementia
Current Aging Science
Title: Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients
Volume: 1 Issue: 3
Author(s): Jennifer Duncan Davis, Anna Podolanczuk, John E. Donahue, Edward Stopa, James V. Hennessey, Lu-Guong Luo, Yow-Pin Lim and Robert A. Stern
Affiliation:
Keywords: Thyroid hormones, thyroxine, Alzheimer's disease, dementia
Abstract: Converging evidence suggests a possible link between thyroid state and Alzheimers disease (AD), including a higher probability of dementia in individuals with higher TSH levels and a two-fold risk of AD in patients with hypothyroidism. Thyroid hormones modulate factors associated with AD, including amyloid precursor protein expression in the brain, suggesting a possible role for thyroid hormone in AD pathology. The present study is the first to directly evaluate brain thyroid hormone levels in AD. Triiodothyronine (T ) and thyroxine (T ) levels were measured with radioimmunoassay (RIA) in post-mortem samples of prefrontal cortex of patients with pathologically confirmed AD, including Braak stage I-II (n=8), Braak stage V-VI (n=8), and controls without any primary neurological disease (n=8). T levels did not differ between groups. T levels were significantly lower in Braak stage V-VI brains relative to controls, but there was no statistically significant difference between T levels in Braak stage I-II versus controls. Results suggest that the conversion of T to T may be affected in advanced AD, perhaps due to alterations in deiodinase activity. Reduced conversion of T to T3 in AD may be associated with both AD pathology and the clinical presentation of dementia.
Export Options
About this article
Cite this article as:
Davis Duncan Jennifer, Podolanczuk Anna, Donahue E. John, Stopa Edward, Hennessey V. James, Luo Lu-Guong, Lim Yow-Pin and Stern A. Robert, Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients, Current Aging Science 2008; 1 (3) . https://dx.doi.org/10.2174/1874609810801030175
DOI https://dx.doi.org/10.2174/1874609810801030175 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alpha<sub>1</sub>-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review
Current Psychopharmacology Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Alzheimer Research Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Growth Factors as Therapeutics for Diabetic Neuropathy
Current Drug Targets Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Social Functioning Across the Course of Schizophrenia
Current Psychiatry Reviews Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Development of Subjective Cognitive Decline
Neuroscience and Biomedical Engineering (Discontinued) BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research “Care-Getting”: A Conceptual Model of Marshalling Support Near the End of Life
Current Aging Science Considering Autotaxin Inhibitors in Terms of 2D-QSAR and 3D-Mapping- Review and Evaluation
Current Medicinal Chemistry Towards Practical Cognitive Assessment for Detection of Early Dementia: A 30-Minute Computerized Battery Discriminates as Well as Longer Testing
Current Alzheimer Research Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design